NewsResearch
The first CAR T-cell therapy is approved
A dated cancer milestone (2017): engineered immune cells enter routine care for some blood cancers. Why it mattered, its limits, and how the field evolved.
Original commentary from the Cancer Explained editorial team.
Historical context: this page explains an event dated 2017. It was published as an explainer on July 12, 2026 and is not breaking news.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Historical milestone — this page describes an event dated 2017. It is not current breaking news.
In brief
The first CAR T-cell therapy is approved (2017). Engineered immune cells enter routine care for some blood cancers.
What happened
The first CAR T-cell therapy is approved, dated to 2017. Engineered immune cells enter routine care for some blood cancers. Specific dates and attributions are held for verification against historical sources.
Why it changed cancer care or understanding
Engineered immune cells enter routine care for some blood cancers. Milestones like this help explain how today's cancer care and understanding came to be.
The context of the time
Set against the knowledge and tools of its time, this step marked a meaningful change in direction.
What to keep in perspective
- A historical milestone reflects the knowledge and standards of its era, not today's.
- Early breakthroughs were often limited, and the field kept evolving afterward.
How the field evolved afterward
Later research built on, refined, and in some cases corrected this development.
Present-day relevance
Leukemia is cancer of the blood-forming tissue, including bone marrow. It is grouped as acute or chronic and by the type of blood cell involved (lymphoid or myeloid). There is no routine screening for leukemia in the general public. It is usually found through blood tests done for symptoms or other reasons.
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
- FDA approves tisagenlecleucel for B-cell ALL (official)
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.